212 related articles for article (PubMed ID: 10083494)
1. Withdrawal versus continuous cyclosporine therapy in kidney transplant recipients of one-haplotype-matched donors.
Chew-Wong A; Alberú J; Abasta-Jiménez M; Alvarez-Sandoval E; Gabilondo-Navarro F; Correa-Rotter R
Transplant Proc; 1999; 31(1-2):1106-9. PubMed ID: 10083494
[No Abstract] [Full Text] [Related]
2. Renal recipients of haploidentical living donors treated with Neoral or conventional cyclosporine: a comparative follow-up of 3 years.
Gracida C; Melchor JL
Transplant Proc; 1998 Aug; 30(5):1742-3. PubMed ID: 9723262
[No Abstract] [Full Text] [Related]
3. Neoral reduces the incidence of acute rejection after renal transplantation.
Sandrini S; Setti G; Gaggia P; Chiappini R; Maffeis R; Tardanico R; Maiorca R
Transplant Proc; 1998 Aug; 30(5):1758-9. PubMed ID: 9723269
[No Abstract] [Full Text] [Related]
4. Cyclosporine from twice to single daily dosing: impact on renal function, mortality, and graft loss.
Bianco PD; Silva HT; Boni R; Machado PG; Pacheco-Silva A; Pestana JO
Transplant Proc; 2002 Nov; 34(7):2920-1. PubMed ID: 12431657
[No Abstract] [Full Text] [Related]
5. Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study.
Wong KM; Cheung CY; Chan YH; Chak WL; Choi KS; Chau KF; Li CS
Transplant Proc; 2000 Nov; 32(7):1721-2. PubMed ID: 11119907
[No Abstract] [Full Text] [Related]
6. Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral.
Cattral MS; Hemming AW; Greig PD; Rowsell C; Chari R; Wright E; Donat D; Cole E; Levy GA
Transplant Proc; 1998 Aug; 30(5):1946. PubMed ID: 9723346
[No Abstract] [Full Text] [Related]
7. Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine.
Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S
Transplant Proc; 1998 Aug; 30(5):1760-1. PubMed ID: 9723270
[No Abstract] [Full Text] [Related]
8. Neoral versus Sandimmune in kidney transplantation.
Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
[No Abstract] [Full Text] [Related]
9. Single center experience of 1500 kidney transplants.
Park K; Kim YS; Kim SI; Kim MS; Moon JI
Transplant Proc; 1998 Nov; 30(7):3088-9. PubMed ID: 9838362
[No Abstract] [Full Text] [Related]
10. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
Park K; Kim MS; Kim SI; Kim YS; Moon JI
Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
[No Abstract] [Full Text] [Related]
11. Impact of cyclosporine dosing frequency on graft function and survival after the conversion from sandimmun to neoral in stable kidney transplanted patients.
Sampaio EL; Park SI; Felipe CR; Silva HT; Pestana JO
Transplant Proc; 2002 Dec; 34(8):3153-61. PubMed ID: 12493405
[No Abstract] [Full Text] [Related]
12. Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor.
Kinukawa T; Ohshima S; Ono Y; Fujita T; Hattori R; Tanaka K
Transplant Proc; 1998 Jun; 30(4):1227-9. PubMed ID: 9636498
[No Abstract] [Full Text] [Related]
13. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone.
Fabrega AJ; Roy G; Reynolds L; Corwin C; Hunsicker L
Transplant Proc; 1998 Jun; 30(4):1335-6. PubMed ID: 9636543
[No Abstract] [Full Text] [Related]
14. Long-term results of kidney grafts surviving beyond the first year: comparison of cyclosporine-based regimens with the azathioprine and steroid regimen.
Rizzolo M; Puggia R; Maresca MC; Calconi G; Vianello A
Transplant Proc; 1998 Aug; 30(5):1751-2. PubMed ID: 9723266
[No Abstract] [Full Text] [Related]
15. Long-term follow-up (5 and 10 years) in recipients of HLA identical living related donor kidney grafts receiving continuous cyclosporine compared with azathioprine.
MacDonald AS; Belitsky P; Bitter-Suermann H; Lawen J; MacSween M; Kiberd B; West K; McAlister VC
Transplant Proc; 1997; 29(1-2):190. PubMed ID: 9122958
[No Abstract] [Full Text] [Related]
16. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.
Lewis RL; Canafax DM; Pettit KG; DiCesare J; Kaniecki DJ; Arnold RJ; Roberts MS
Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203
[No Abstract] [Full Text] [Related]
17. Complete withdrawal of immunosuppression in kidney allograft recipients: a prospective study in rhesus monkeys.
Jonker M; van den Hout Y; Neuhaus P; Ringers J; Kuhn EM; Bruijn JA; Schuurman HJ; Noort R; Bontrop RE; Claas FH; van Rood JJ
Transplant Proc; 1998 Aug; 30(5):2451-3. PubMed ID: 9723534
[No Abstract] [Full Text] [Related]
18. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
19. Long-term effects of single versus double CsA dosing in kidney transplantation.
Tarantino A; Montagnino G; Cesana B; Aroldi A; Campise M; Passerini P; Ponticelli C
Transplant Proc; 2001; 33(7-8):3409-10. PubMed ID: 11750459
[No Abstract] [Full Text] [Related]
20. Long-term evaluation of two protocols of elective cyclosporine withdrawal in renal transplant recipients.
Keitel E; Michelon T; Dominguez V; Bittar AE; Santos AF; Goldani JC; Neumann J; Garcia VD
Transplant Proc; 1999 Nov; 31(7):3013-5. PubMed ID: 10578370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
